Table 1.
Characteristics of patients, MRI, and histopathological findings.
| ALT/WDLS (N = 56) | Lipoma (N = 89) | p value | |
|---|---|---|---|
| Clinical findings | |||
| Age | < 0.001 | ||
| Median (range) | 64.0 ± 13.29 (30–87) | 55.7 ± 14.60 (18–83) | |
| Sex: n (%) | 0.547 | ||
| Male | 32 (57.1%) | 45 (50.6%) | |
| Female | 24 (42.9%) | 44 (49.4%) | |
| Symptoms: n (%) | 6 (10.7%) | 4 (4.5%) | 0.150 |
| Tumor site: n (%) | < 0.0001 | ||
| Upper limb | 5 (8.9%) | 29 (32.6%) | |
| Lower limb | 39 (69.7%) | 24 (27.0%) | |
| Other | 12 (21.4%)a | 36 (40.4%)b | |
| Tumor depth: n (%) | < 0.0001 | ||
| Superficial | 0 (0%) | 29 (32.6%) | |
| Deep | 56 (100%) | 60 (67.4%) | |
| Tumor size (cm) | < 0.0001 | ||
| Median | 17.2 ± 6.7 | 9.7 ± 4.2 | |
| MRI findings: n (%) | |||
| Thick septa (> 2 mm) | 52 (92.9%) | 52 (58.4%) | < 0.0001 |
| Enhancement (septa and/or nodular lesions) (n = 20) | 20 (100%) | 4 (20.0%) | < 0.0001 |
| Neurovascular involvement | 5 (8.9%) | 1 (1.1%) | 0.023 |
| Histopathological findings: n (%) | |||
| Nuclear atypia | 10 (17.9%) | 0 (0%) | < 0.0001 |
| Nuclear enlargement | 26 (46.4%) | 8 (9.0%) | < 0.0001 |
| Difference in size of adipocytes | 26 (46.4%) | 24 (27.0%) | 0.016 |
| Proliferation of fibrous septa | 2 (3.6%) | 3 (3.4%) | 0.949 |
| Lipoblasts | 11 (19.6%) | 1 (1.1%) | < 0.0001 |
| FISH: positive number / n = total number (%) | |||
| MDM2 | 37/n = 46 (80.4%) | 0/n = 73 (0%) | < 0.0001 |
| CDK4 | 18/n = 33 (54.5%) | 0/n = 49 (0%) | < 0.0001 |
aneck (n = 4), chest (n = 2), retroperitoneum (n = 2), and back (n = 2).
bneck (n = 15), chest (n = 13), back (n = 6), and abdomen (n = 2).
MRI magnetic resonance imaging, ALT atypical lipomatous tumor, WDLS well-differentiated liposarcoma, FISH Fluorescence in Situ Hybridization, MDM2 murine double-minute 2, CDK4 cyclin-dependent kinase 4.